Cladribine
| Evidence Level: L5 | Predicted Indications: 7 |
Table of Contents
- Cladribine
- Cladribine: From Original Indication (Not Specified in Evidence Pack) to Parameningeal Embryonal Rhabdomyosarcoma
Using the drug-repurposing evidence pack you provided, here is the evaluation report. Note upfront: the JSON’s own taiwan_regulatory block, TFDA remediation source, and TW-DB00242 candidate ID all indicate this is a Taiwan (TFDA) dataset, not India/CDSCO as the generic prompt header states — I’ve labeled the market-status section accordingly rather than guessing at India-specific data that isn’t in the pack.
Also flagging per the “no guessing” rule: drug.original_indications is empty and taiwan_regulatory.licenses is empty, so the original indication cannot be extracted from this evidence pack — I’ve marked it as a data gap rather than filling it in from outside knowledge.
Cladribine: From Original Indication (Not Specified in Evidence Pack) to Parameningeal Embryonal Rhabdomyosarcoma
One-Sentence Summary
Cladribine’s original approved indication is not recorded in this evidence pack (drug-level data gap), and the compound is not currently marketed in Taiwan. The TxGNN model predicts potential efficacy for Parameningeal Embryonal Rhabdomyosarcoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph association with no independent validation.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (data gap — drug.original_indications and taiwan_regulatory.licenses are both empty) |
| Predicted New Indication | Parameningeal Embryonal Rhabdomyosarcoma |
| TxGNN Prediction Score | 99.77% (raw score 0.9977; graph rank 4548) |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| Taiwan Market Status | Not marketed (Not Marketed) |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data for cladribine is flagged as a High-severity data gap (DG002) in this evidence pack — no original_moa value is available directly from DrugBank. However, the pack’s own mechanistic-rationale notes (attached to the related “rhabdomyosarcoma (disease)” candidate) describe cladribine as a purine nucleoside analog whose cytotoxic selectivity depends on a high intracellular ratio of deoxycytidine kinase (dCK) to 5′-nucleotidase (5′-NT) activity — a profile characteristic of lymphoid lineage cells (B/T cells), which is consistent with cladribine’s known clinical use in hairy-cell leukemia-type lymphoid malignancies.
Because the original indication is not recorded here, a direct comparison between the original and predicted indications cannot be made from this evidence pack alone. What can be assessed is the biological plausibility of extending a lymphoid-selective cytotoxic mechanism to rhabdomyosarcoma, which is a tumor of myogenic (skeletal muscle precursor) lineage, not lymphoid lineage.
On that basis, the evidence pack’s own rationale concludes the mechanistic fit is weak: rhabdomyosarcoma’s cell-of-origin biology does not match the dCK/5′-NT selectivity profile that underlies cladribine’s known activity, and no published data demonstrate this ratio in rhabdomyosarcoma. The high TxGNN score (99.77%) reflects a strong graph-embedding association, not a validated pharmacological mechanism — this is the classic profile of an L5 (model-prediction-only) candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
(Confirmed by explicit zero-result queries against ClinicalTrials.gov and ICTRP for “parameningeal embryonal rhabdomyosarcoma” + cladribine, dated 2026-03-27.)
Literature Evidence
Currently no related literature available.
(Confirmed by an explicit zero-result PubMed query for “parameningeal embryonal rhabdomyosarcoma” + cladribine, dated 2026-03-27. Note: a separate, lower-ranked candidate indication in this batch — “liver sarcoma” — did return one tangentially related case report (PMID 15241520) on cladribine in smoldering systemic mastocytosis, but the evidence pack’s own rationale flags that match as likely a keyword/indexing overlap rather than genuine clinical evidence, and it does not apply to the top-ranked indication evaluated in this report.)
Taiwan Market Information
No approved products are currently registered in Taiwan for cladribine (market_status: Not marketed / Not Marketed; total_licenses: 0). No license records are available to summarize.
Cytotoxicity
Cladribine is classified here as antineoplastic based on its documented mechanism (purine nucleoside antimetabolite with dCK/5′-NT-dependent cytotoxic selectivity), which falls within a recognized cytotoxic chemotherapy category.
| Item | Content |
|---|---|
| Cytotoxicity Classification | Conventional cytotoxic (purine nucleoside antimetabolite) |
| Myelosuppression Risk | Please refer to the package insert warnings and precautions (no specific toxicity data in this evidence pack; TFDA label data is a Blocking data gap — DG001) |
| Emetogenicity Classification | Please refer to the package insert warnings and precautions (no data in this evidence pack) |
| Monitoring Items | Please refer to the package insert warnings and precautions (no data in this evidence pack) |
| Handling Protection | Cytotoxic drug handling regulations should apply, consistent with its conventional cytotoxic classification |
Safety Considerations
- Drug Interactions: DDI screening returned 344 total interactions. Major-level interactions include corticosteroids (Hydrocortisone, Triamcinolone, Dexamethasone, Betamethasone, Budesonide, Prednisolone, Prednisone, Triamcinolone ophthalmic), radioimmunotherapy/radiopharmaceutical agents (Ibritumomab tiuxetan, Iobenguane I-131, Tositumomab, Tositumomab I-131, Samarium (153Sm) lexidronam, Strontium chloride Sr-89), and Deferiprone. Moderate-level interactions include Dipyridamole, Cilostazol, Eltrombopag, and Palifermin. Acetylsalicylic acid shows an interaction of unclassified (“Unknown”) severity.
Key warnings and contraindications are not available in this evidence pack — this is flagged as a Blocking data gap (DG001: TFDA label warnings/contraindications), meaning this candidate cannot yet complete a full S1 safety pre-screen.
Conclusion and Next Steps
Decision: Hold
Rationale: This candidate has zero clinical trial or literature support, a mechanistic rationale that the evidence pack itself assesses as weak (lymphoid-selective mechanism vs. myogenic tumor biology), and a Blocking-severity data gap on TFDA safety labeling (DG001) that prevents even an initial safety screen. The high TxGNN score alone (L5, prediction-only) is insufficient to advance this candidate.
To proceed, the following is needed:
- TFDA label warnings/contraindications (DG001 — Blocking; required before any S1 safety evaluation)
- Confirmed mechanism of action from DrugBank (DG002 — required for mechanistic-link analysis)
- The original approved indication(s) for cladribine, to properly assess original-vs-new indication similarity
- Preclinical or in-vitro data establishing whether rhabdomyosarcoma cell lines exhibit the dCK/5′-NT activity profile relevant to cladribine’s cytotoxic selectivity
- Any future clinical trial, case report, or preclinical publication specifically evaluating cladribine in rhabdomyosarcoma (none currently exist)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.